← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
AntibodystaleRocheApproved

Oxaliplatin;Capecitabine;Bevacizumab (Oxaliplatin;Capecitabine;Bevacizumab)

Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Approved#항체#면역항체+4
임상시험 2상태 ACTIVE
CGTAAVBiologicstalePfizerPhase 3

PF-07055480 (PF-07055480, PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy, giroctocogene fitelparovec)

Hemophilia A · Hemophilia A

#HemophiliaA#CGT#Phase3#세포유전치료#CAR-T+2
임상시험 2상태 RECRUITING
ADCBiologicstalePfizerPhase 3

PF-08046054 (PF-08046054)

Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma

#Non-smallCellCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstalePyxis Oncology, IncthroughPhase 2

PYX-201 (PYX-201)

Advanced Solid Tumors · Solid Tumor

#SolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 2상태 RECRUITING
AntibodystaleEli LillyPhase 2

Penpulimab combined with cetuximab (Penpulimab combined with cetuximab)

Head and Neck Neoplasms; Recurrent Disease · Head and Neck Neoplasms

#HeadandNeckNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6.24%임상시험 2상태 ACTIVE
CGTBiologicstaleNektar TherapeuticsPhase 1

Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Polymer-conjugated IL-15 Receptor Agonist NKTR-255)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Puxitatug Samrotecan (Puxitatug Samrotecan)

Endometrial Cancer; Malignant Solid Tumour · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleQilu Pharmaceutical Co., Ltd.Phase 1

QLS5132 (QLS5132)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

RC118-ADC (RC118-ADC)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 1

RC98 (RC98)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 1

Ris-Rez (Ris-Rez)

Neoplasms · Neoplasms, Lung

#NeoplasmsLung#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
AntibodystaleRochePhase 2

rituximab (Rituxan, Rituxan (rituximab))

Rheumatoid Arthritis · Lupus Erythematosus, Systemic

#LupusErythematosusSystemic#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Robatumumab (Robatumumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 DISCONTINUED
ADCBiologicstaleSilverback TherapeuticsPhase 2

SBT6050 (SBT6050)

HER2-positive Breast Cancer; HER2-positive Gastric Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 2상태 ACTIVE
CGTBiologicstaleSeattle Children's HospitalPhase 1

SC-CAR.GPC3xIL15.21 CAR T cells (SC-CAR.GPC3xIL15.21 CAR T cells)

Solid Tumor (Excluding CNS); Liver Cell Carcinoma · Solid Tumor (Excluding CNS)

#SolidTumorExcludingCNS#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleSana BiotechnologyPhase 1

SC291 (SC291)

Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · Lupus Erythematosus

#LupusErythematosus#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 2상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SEA-TGT (SEA-TGT)

Non-small Cell Lung Cancer; Gastric Carcinoma · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 33.3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleSeagen Inc.Phase 1

SGN-75 (SGN-75)

Renal Cell Carcinoma · Carcinoma, Renal Cell

#CarcinomaRenalCell#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 DISCONTINUED

67 / 177 페이지

← 이전다음 →